CLINICAL TRIALS PROFILE FOR IMP4297
✉ Email this page to a colleague
Clinical Trials for IMP4297
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03507543 ↗ | The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors | Completed | Impact Therapeutics, Inc. | Phase 1 | This is a phase 1, First-In-Human, open label study, trialing a new PARP (poly-ADP ribose polymerase) inhibitor medication IMP4297 in participants with advanced solid tumour. |
| NCT03508011 ↗ | A Study of IMP4297 in Patients With Advanced Solid Tumors | Completed | Impact Therapeutics, Inc. | Phase 1 | This is a Phase I, first-in-human, open-label, dose-escalation study of IMP4297 administered orally once every day to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable. Patients with advanced breast cancer, ovarian cancer or prostate cancer are preferred. There are two stages to this study: a dose-escalation stage and a dose-expansion stage. |
| NCT04057729 ↗ | IMP4297 Food Effect Trial in Healthy Volunteers | Completed | Impact Therapeutics, Inc. | Phase 1 | A phase I, single-site, open-label, randomized, single-dose, two-way crossover study to evaluate the effect of food on the pharmacokinetic characteristics of IMP4297 capsules in China |
| NCT04089189 ↗ | Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer | Recruiting | Impact Therapeutics, Inc. | Phase 2 | A phase II, multi-center, open-label, single-arm, non-randomized study to evaluate the efficacy, safety and tolerability of IMP4297 capsules in subjects with germline and/or systemic BRCA1/2 mutated advanced ovarian cancer in china |
| NCT04169997 ↗ | A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer | Recruiting | Impact Therapeutics, Inc. | Phase 3 | IMP4297 is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate Efficacy and Safety of IMP4297 for Maintenance Treatment |
| NCT04351165 ↗ | BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects | Completed | Impact Therapeutics, Inc. | Phase 1 | An open-label, randomized, single-dose, 2-way crossover study to compare the bioavailability of two IMP4297 formulations (20 mg capsules and 10 mg capsules) after single oral administration of 100 mg IMP4297 under fasted condition in healthy male subjects |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for IMP4297
Condition Name
Clinical Trial Locations for IMP4297
Clinical Trial Progress for IMP4297
Clinical Trial Phase
Clinical Trial Sponsors for IMP4297
Sponsor Name
